ANI Pharmaceuticals (ANIP) Receiving Somewhat Positive Media Coverage, Study Finds

Press coverage about ANI Pharmaceuticals (NASDAQ:ANIP) has trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ANI Pharmaceuticals earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 46.2432372075271 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Several equities analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a research report on Tuesday, November 7th. Canaccord Genuity restated a “buy” rating and set a $66.00 price objective (up previously from $60.00) on shares of ANI Pharmaceuticals in a research report on Monday, October 16th. ValuEngine lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 14th. Finally, TheStreet upgraded shares of ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, November 16th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $70.50.

Shares of ANI Pharmaceuticals (NASDAQ ANIP) opened at $66.27 on Monday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 3.45. ANI Pharmaceuticals has a 52 week low of $42.23 and a 52 week high of $74.70. The company has a market cap of $772.24, a PE ratio of 19.78 and a beta of 2.91.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The company had revenue of $48.16 million during the quarter, compared to analyst estimates of $48.12 million. During the same period in the prior year, the firm earned $1.09 earnings per share. The business’s quarterly revenue was up 25.0% on a year-over-year basis. equities research analysts predict that ANI Pharmaceuticals will post 3.59 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://sportsperspectives.com/2017/12/18/ani-pharmaceuticals-anip-receiving-somewhat-positive-media-coverage-study-finds.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply